Cite
HARVARD Citation
Lakhani, N. et al. (n.d.). 295 First-in-human Phase I trial of IBI188, an anti-CD47 targeting monoclonal antibody, in patients with advanced solid tumors and lymphomas. Journal for immunotherapy of cancer. p. A322. [Online].